Swiss pharma giant Novartis (NOVN: VX) has filed a lawsuit against the US Department of Health and Human Services (HHS) over a proposed cash rebate model.
The model relates to the 340B program, which mandates that drug manufacturers provide discounted medicines to covered entities such as hospitals and clinics that treat vulnerable populations.
The HHS opted to block a plan which would have seen health providers paying the full price for drugs upfront, followed by a rebate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze